Any current/future new fundraising through debt or equity?

There is an ongoing internal discussion and process related to promoter holding dilution to comply with SEBI regulations, requiring promoter holding to reduce to 75%. This implies potential stake sale or equity dilution. Glenmark Pharma is approaching some investors for stake sale, and management has participated in these discussions. No explicit mention of new debt fundraising. Capex guidance for FY24 is INR 150-200 crores, to be funded internally as the company remains net debt-free with strong cash balances. Free cash flow generation is strong, and the company plans to continue distributing

Any current/future capex/capital investment/strategic investment?

Dahej capacity was brought online in Q4 and has already reached 80% utilization; additional capacity expansions will continue to avoid disadvantaging the business. Backward integration project is partially commissioned; full capacity expected this year, with a commercial project starting Q2 expected to improve gross margin by 5%-7% on a ~INR100 crore product. Solapur capex to commence construction this financial year, planned in phases; capacity is multipurpose for both CDMO and generics. FY’24 capex guidance is INR150-200 crores, continuing calibrated investment approach. Industry capex build

Future growth expectations in sales/revenue/volumes?

The company expects revenue growth of around 12% to 15% for FY24, maintaining conservative guidance despite strong Q4 performance. Growth is largely volume-driven, with new products and capacity expansions contributing significantly. The Dahej facility capacity brought online in Q4 has reached 80% utilization, signaling a strong growth lever going forward. The external business, especially regulated markets, showed growth normalization in second half and strong demand in Q4. The CDMO segment aims to double its revenue contribution from approx. INR150-170 crores (7-8%) to around 15% ove

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark Life Sciences expects revenue growth of 12-15% for FY24, maintaining a stable outlook despite Q4’s strong performance which was slightly above guidance. EBITDA margin guidance is around 30-31%, with a possibility of reaching ~33% if all growth levers fire positively, but the company remains cautious due to market volatility. The company aims to nearly double certain segments (e.g., from INR150 crores to INR600 crores in ~4-5 years), indicating robust medium-term growth ambitions, especially in complex APIs, iron compounds, and oncology. PAT saw a 39% sequential growth in Q4 and

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention current or expected orderbook or pending orders in quantified terms. However, the management indicates strong demand recovery and capacity utilization: - Dahej capacity brought online in Q4 already at 80% utilization, indicating robust order inflow. - Good visibility on business with numerous new molecules and customers contributing to a pipeline of around 140 molecules. - Increasing momentum in China de-risking leading to new customer filings and diversified supply chains. - Growth levers include high-complexity APIs, iron compounds, and onco

Alivus LifeQ4 FY23Pharmaceuticals & Biotechnology

Alivus Life Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,387P/E: 27.4Market Cap: ₹17.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects revenue growth of around 12% to 15% for FY24, maintaining conservative guidance despite strong Q4 performance.
Growth is largely volume-driven, with new products and capacity expansions contributing significantly.
The Dahej facility capacity brought online in Q4 has reached 80% utilization, signaling a strong growth lever going forward.
The external business, especially regulated markets, showed growth normalization in second half and strong demand in Q4.
The CDMO segment aims to double its revenue contribution from approx. INR150-170 crores (7-8%) to around 15% over 4-5 years, implying potential revenue of INR600 crores.
Introduction of new complex molecules, oncology compounds, and geographic expansion expected to drive future growth.
The product basket expanded to 139 molecules with 700 customers globally, supporting diversified growth.
Despite pricing pressures, especially in the US market, margins are expected to remain sustainable due to product diversity and new product introductions.

Margin guidance

Category 3

Glenmark Life Sciences expects revenue growth of 12-15% for FY24, maintaining a stable outlook despite Q4’s strong performance which was slightly above guidance.
EBITDA margin guidance is around 30-31%, with a possibility of reaching ~33% if all growth levers fire positively, but the company remains cautious due to market volatility.
The company aims to nearly double certain segments (e.g., from INR150 crores to INR600 crores in ~4-5 years), indicating robust medium-term growth ambitions, especially in complex APIs, iron compounds, and oncology.
PAT saw a 39% sequential growth in Q4 and 48% YoY, reflecting improved profitability driven by better gross margins and lower costs, with continued margin sustainability expected.
The business pipeline includes 139 molecules and 20 complex molecules in the R&D pipeline, supporting sustainable long-term growth.
Free cash flow generation of INR200-300 crores annually supports dividends and reinvestment.

See what Alivus Life management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is an ongoing internal discussion and process related to promoter holding dilution to comply with SEBI regulations, requiring promoter holding to reduce to 75%. This implies potential stake sale or equity dilution.
Glenmark Pharma is approaching some investors for stake sale, and management has participated in these discussions.
No explicit mention of new debt fundraising.
Capex guidance for FY24 is INR 150-200 crores, to be funded internally as the company remains net debt-free with strong cash balances.
Free cash flow generation is strong, and the company plans to continue distributing free cash mostly through dividends.
Management aims to be measured and cautious in capital allocation and fundraising, with plans to grow the CDMO business and overall capacity cautiously.

Order book

Yes

The transcript does not explicitly mention current or expected orderbook or pending orders in quantified terms.
However, the management indicates strong demand recovery and capacity utilization:
- Dahej capacity brought online in Q4 already at 80% utilization, indicating robust order inflow.
- Good visibility on business with numerous new molecules and customers contributing to a pipeline of around 140 molecules.
- Increasing momentum in China de-risking leading to new customer filings and diversified supply chains.
- Growth levers include high-complexity APIs, iron compounds, and oncology compounds.
CDMO projects have picked up due to additional customer indications and inventory rationalizations.
Overall, management expresses optimism about demand and intends to stick to their growth guidance with no specific order backlog numbers disclosed.

See what Alivus Life management said on order book — free account, 30 seconds.

Capex plans

Yes

Dahej capacity was brought online in Q4 and has already reached 80% utilization; additional capacity expansions will continue to avoid disadvantaging the business.
Backward integration project is partially commissioned; full capacity expected this year, with a commercial project starting Q2 expected to improve gross margin by 5%-7% on a ~INR100 crore product.
Solapur capex to commence construction this financial year, planned in phases; capacity is multipurpose for both CDMO and generics.
FY’24 capex guidance is INR150-200 crores, continuing calibrated investment approach.
Industry capex buildup continues but is calibrated; Glenmark's multipurpose and fungible capacities reduce the need for large investments.
Working capital days peaked at 178 in Q3 and expected to reduce slightly to around 160-170 days going forward.
Free cash flow generation will support continued dividend payouts alongside capex requirements.

Track Alivus Life — get its next earnings analysis in your feed

Margin guidance

Category 3

Glenmark Life Sciences expects revenue growth of 12-15% for FY24, maintaining a stable outlook despite Q4’s strong performance which was slightly above guidance.
EBITDA margin guidance is around 30-31%, with a possibility of reaching ~33% if all growth levers fire positively, but the company remains cautious due to market volatility.
The company aims to nearly double certain segments (e.g., from INR150 crores to INR600 crores in ~4-5 years), indicating robust medium-term growth ambitions, especially in complex APIs, iron compounds, and oncology.
PAT saw a 39% sequential growth in Q4 and 48% YoY, reflecting improved profitability driven by better gross margins and lower costs, with continued margin sustainability expected.
The business pipeline includes 139 molecules and 20 complex molecules in the R&D pipeline, supporting sustainable long-term growth.
Free cash flow generation of INR200-300 crores annually supports dividends and reinvestment.

Order book

Yes

The transcript does not explicitly mention current or expected orderbook or pending orders in quantified terms.
However, the management indicates strong demand recovery and capacity utilization:
- Dahej capacity brought online in Q4 already at 80% utilization, indicating robust order inflow.
- Good visibility on business with numerous new molecules and customers contributing to a pipeline of around 140 molecules.
- Increasing momentum in China de-risking leading to new customer filings and diversified supply chains.
- Growth levers include high-complexity APIs, iron compounds, and oncology compounds.
CDMO projects have picked up due to additional customer indications and inventory rationalizations.
Overall, management expresses optimism about demand and intends to stick to their growth guidance with no specific order backlog numbers disclosed.

How does Alivus Life rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlivus Life

Rev 3Mar 3

See where Alivus Life sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alivus Life rank in Pharmaceuticals & Biotechnology?

Compare Alivus Life against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alivus Life's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltd vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Alivus Life Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Alivus Life rank in Pharmaceuticals & Biotechnology?

Continue your research

What Alivus Life's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season